Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PPID | Q08752 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26260125 | 0.90 | KMT2A (0.49) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL26265498 | 0.90 | KMT2A (0.49) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL30546860 | 0.83 | ALDH1A1 (0.48) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL30453137 | 0.83 | ALDH1A1 (0.48) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL24257514 | 0.83 | ALDH1A1 (0.48) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL14150287 | 0.83 | KMT2A (0.48) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL30452692 | 0.81 | EGLN1 (0.46) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL24257792 | 0.81 | EGLN1 (0.46) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL24257580 | 0.81 | KMT2A (0.41) | KMT2AMEN1L3MBTL1PPIDMAPT | |
| SCHEMBL24257835 | 0.81 | VEGFA (0.49) | KMT2AMEN1L3MBTL1PPIDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | KMT2A 868/4885MEN1 4845/4885L3MBTL1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.